Myrelez (Lanreotide Acetate)

Lanreotide acetate mimics the natural hormone somatostatin and binds to somatostatin receptors, especially subtypes SSTR2 and SSTR5. This binding blocks signaling pathways that stimulate growth hormone and other endocrine hormones, thereby reducing their secretion and limiting tumor‑related hormone excess.

The specific dose and dosing interval of Myrelez are determined by the prescribing physician based on the individual patient's condition, response, and tolerability. Healthcare professionals follow approved labeling and clinical guidelines when selecting the appropriate regimen.

Safety data for lanreotide acetate in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Myrelez, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Myrelez (lanreotide acetate) and other agents such as octreotide share a similar mechanism of receptor binding but differ in formulation and dosing frequency. Lanreotide is often administered as a long‑acting subcutaneous injection, allowing less frequent dosing, whereas octreotide may require more frequent injections or continuous infusion.

Myrelez should be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

Myrelez is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a qualified healthcare professional or trained patient following aseptic technique and the specific instructions provided with the product.

Serious adverse events, though uncommon, include acute pancreatitis, severe hyperglycemia, cardiac arrhythmias, anaphylactic reactions, and injection‑site necrosis. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Myrelez is contraindicated in patients with known hypersensitivity to lanreotide acetate or any excipients in the formulation. Caution is also advised for individuals with uncontrolled diabetes, severe gallbladder disease, or significant cardiac arrhythmias, and it should be avoided in such cases unless a specialist determines the benefits outweigh the risks.